Project Grant R01HL178815
Award Date
5/21/25
Completion Date
3/31/29
Dollars Obligated
$889K
Federal Agency
National Heart Lung and Blood Institute
Federal Grant Program
93.837
Assistance Type
Project Grant
Place of Performance
Massachusetts, USA
Similar Awards
The National Heart, Lung, and Blood Institute (NHLBI), a division of the National Institutes of Health (NIH), awarded a $793,956 Project Grant (CFDA 93.837 Cardiovascular Diseases Research) to Resuscitation Innovations LLC, operating as Advancedcpr Solutions LLC, to develop innovative treatments for refractory cardiac arrest. The project aims to improve survival rates for the approximately 750,000 patients annually who do not recover from cardiac arrest using current interventions. Specifically,...
The federal Project Grant award R42HL170864, funded by the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837), is focused on developing and demonstrating a high-volume manufacturing technology for microfluidic oxygenators to treat respiratory failure. The $294,063 award to Biomembretics, Inc. aims to advance the commercialization of this innovative medical technology. The project will define the target product profile, conduct...
This Project Grant award for $822,181 from the National Heart, Lung, and Blood Institute (CFDA 93.837 Cardiovascular Diseases Research) supports research to advance understanding of how the physiologic response to epinephrine during pediatric in-hospital cardiac arrest (IHCA) impacts resuscitation outcomes. The research will leverage data from the Pediatric Resuscitation Quality Collaborative (PediRes-Q) network to examine the relationship between epinephrine dosing, physiologic response, and...
The National Heart, Lung, and Blood Institute (NHLBI) awarded Vivacelle Bio Inc. a $559,138 Project Grant under the Cardiovascular Diseases Research Federal Grant Program (CFDA 93.837) to develop VBI-1, a novel treatment protocol for outpatient cardiac arrest. VBI-1 is a proprietary formulation composed of micelles and liposomes designed to address cardiac ischemia reperfusion injury by acting as a colloidal volume expander, absorbing nitric oxide and free radicals, and carrying and releasing...
This Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research program (CFDA 93.837), provides $444,210 to the Children's Hospital of Philadelphia (CHOP) to conduct a 5-year observational study on post-cardiac arrest syndrome in critically ill children. The study will leverage advanced echocardiographic imaging and biomarker assessments to examine associations between myocardial dysfunction, inflammation, and clinical outcomes in...
This Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research program (CFDA 93.837), provides $833,681 to The Children's Hospital Corporation (Boston Children's Hospital) to conduct research aimed at understanding the role of endothelial epsins in regulating myocardial ischemia and heart regeneration. The research seeks to uncover novel molecular mechanisms and identify new therapeutic targets to improve treatment of ischemic...
This $124,536 Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837) will support research at The General Hospital Corporation (doing business as Massachusetts General Hospital) on the protective role of B cells in hyperoxic lung injury. The key objectives are to: Characterize the dynamics of B cell responses during hyperoxia exposure and examine the protective impacts of B cell supplementation, including...
The National Heart, Lung, and Blood Institute (NHLBI) awarded a $735,939 Project Grant under the Cardiovascular Diseases Research program (CFDA 93.837) to The General Hospital Corporation, doing business as Massachusetts General Hospital (MGH). The grant aims to develop and validate new technologies for accurate, rapid, and high-frequency point-of-care blood gas analysis. Specifically, the project will create a miniaturized, automated device that attaches to a standard arterial catheter setup,...
This Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research program (CFDA 93.837), aims to develop and test a bidirectional synchronous flow-controlled ventilation system to improve oxygenation and ventilation in Acute Respiratory Distress Syndrome (ARDS). The $1,160,157 award, effective September 1, 2024 through August 31, 2025, will fund a Phase 1 SBIR project by Liberandum Technologies, Inc. to design, build, and evaluate a...
This federal Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research program (CFDA 93.837), will provide $127,305 to The Children's Hospital Corporation (dba Boston Children's Hospital) for a research project titled "Unraveling Immune Cell Interactions and Multicellular Dynamics in GNAQ-Driven Capillary Malformation." The project aims to study the mechanisms behind capillary malformations, which are vascular...